Patents by Inventor Anthony Ratcliffe
Anthony Ratcliffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200343074Abstract: Provided are methods, apparatus and systems for stabilization of a glow discharge from a plasma. Also provided are methods, apparatus and systems for processing optical signals from a stabilised glow plasma with enhanced signal to noise recovery. A first method comprises: generating an electric field within a plasma cell using an alternating excitation voltage to excite particles within the cell, to produce a glow discharge from a plasma in the plasma cell in a resonant condition; monitoring, in each excitation cycle of the alternating excitation voltage, one or more signals that correlate with glow discharge optical emissions from the plasma in the plasma cell; and, in response to said monitoring, controlling one or more operating conditions for the plasma cell to maintain the glow discharge emissions from the plasma within a desired operating range in each excitation cycle of the alternating excitation voltage.Type: ApplicationFiled: April 6, 2020Publication date: October 29, 2020Applicant: Servomex Group LimitedInventors: Bahram Alizadeh, Martin Lopez, Michael Anthony Ratcliffe, Nicky Jay Batson
-
Patent number: 9820847Abstract: Synthetic structures for fibrous soft tissue repair include a polymeric fibrillar structure that exhibits mechanical properties of the human fibrous soft tissue.Type: GrantFiled: August 17, 2007Date of Patent: November 21, 2017Assignee: Synthasome Inc.Inventors: Anthony Ratcliffe, Andreas Kern
-
Patent number: 9597430Abstract: Synthetic structures for soft tissue repair include a multi-layer planar fibrillar structure having layers which are intermittently secured to each other and which approximates mechanical properties comparable to those of soft tissue. In embodiments, the fibrillar structure possesses an intermittently secured edge portion secured by intermittent welds. In embodiments, the multi layer planar fibrillar structure includes a bioactive agent.Type: GrantFiled: July 31, 2009Date of Patent: March 21, 2017Assignee: Synthasome, Inc.Inventors: Anthony Ratcliffe, Andreas Kern, Mohammad Sotoudeh, Fatemeh Ratcliffe
-
Publication number: 20170055561Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: October 3, 2016Publication date: March 2, 2017Inventors: Gail K. Naughton, David L. Horwitz, Mark Applegate, Joan Zeltinger, Jonathan Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Patent number: 9458486Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: GrantFiled: March 15, 2013Date of Patent: October 4, 2016Assignee: Allergen, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark Applegate, Joan Zeltinger, Jonathan Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20160175479Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: ApplicationFiled: December 22, 2015Publication date: June 23, 2016Inventor: Anthony Ratcliffe
-
Patent number: 9216194Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: GrantFiled: August 19, 2014Date of Patent: December 22, 2015Assignee: Synthasome, Inc.Inventor: Anthony Ratcliffe
-
Publication number: 20150037884Abstract: A tissue engineered construct made totally or in part from biocompatible materials and mammalian cells and/or cell products is provided. These constructs are useful in regenerating complex tissues such as bone, ligament and tendon, which may fabricated into medical devices suitable for use in the treatment of injuries and maladies such as rotator cuff injuries, periodontal disease and hernia.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: Anthony Ratcliffe, Andreas Kern, Fatemeh Ratcliffe
-
Publication number: 20140357716Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventor: Anthony Ratcliffe
-
Patent number: 8883182Abstract: The present invention provides a composition and method for the covalent binding of a hydrogel to an extracellular matrix (ECM). Therapeutic applications include tissue repair and delivery of drugs or cells.Type: GrantFiled: October 9, 2004Date of Patent: November 11, 2014Assignee: Synthasome, Inc.Inventors: Anthony Ratcliffe, Jennifer H. Elisseeff, Dongan Wang
-
Patent number: 8864844Abstract: A tissue engineered construct made totally or in part from biocompatible materials and mammalian cells and/or cell products is provided. These constructs are useful in regenerating complex tissues such as bone, ligament and tendon, which may fabricated into medical devices suitable for use in the treatment of injuries and maladies such as rotator cuff injuries, periodontal disease and hernia.Type: GrantFiled: August 9, 2007Date of Patent: October 21, 2014Assignee: Synthasome, Inc.Inventors: Anthony Ratcliffe, Andreas Kern, Fatemeh Ratcliffe
-
Patent number: 8808730Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: GrantFiled: November 5, 2013Date of Patent: August 19, 2014Assignee: Synthasome, Inc.Inventor: Anthony Ratcliffe
-
Publication number: 20140065201Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: ApplicationFiled: November 5, 2013Publication date: March 6, 2014Applicant: Synthasome, Inc.Inventor: Anthony Ratcliffe
-
Patent number: 8574620Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: GrantFiled: May 3, 2011Date of Patent: November 5, 2013Assignee: Synthasome, Inc.Inventor: Anthony Ratcliffe
-
Patent number: 8476231Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: GrantFiled: March 9, 2012Date of Patent: July 2, 2013Assignee: Allergan, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Patent number: 8361485Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.Type: GrantFiled: October 3, 2006Date of Patent: January 29, 2013Assignee: SkinMedica, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20120230940Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicant: SkinMedica. Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Patent number: 8138147Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.Type: GrantFiled: January 6, 2009Date of Patent: March 20, 2012Assignee: Skinmedica, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20110206634Abstract: The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site.Type: ApplicationFiled: May 3, 2011Publication date: August 25, 2011Applicant: SYNTHASOME, INC.Inventor: Anthony Ratcliffe
-
Publication number: 20110111034Abstract: The present invention relates to the covalent binding of a hydrogel to an extracellular matrix (ECM). The integration of the hydrogel with the tissue is superior to that in previous techniques. Moreover, unlike previous techniques, the present invention does not require a photoinitiator. Potential therapeutic applications include tissue repair and delivery of drugs or cells. The ECM is first exposed, then treated with a priming agent. Then a polymerizable agent is added and crosslinked to the ECM. Two primary embodiments of methods are disclosed. In the first, the priming agent is an oxidizer which creates tyrosyl radicals in the ECM, which are then bound by acrylate groups in the polymerizable agent. In the second, the priming agent contains aldehydes which bind amino groups in the ECM.Type: ApplicationFiled: January 18, 2011Publication date: May 12, 2011Inventors: Dong-an Wang, Anthony Ratcliffe, Jennifer H. Elisseeff